Young MR - Search Results

1

Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation.

Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR, Colburn NH. Hsu TC, et al. Among authors: young mr. Cancer Res. 2001 May 15;61(10):4160-8. Cancer Res. 2001. PMID: 11358840

2

Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently.

Young MR, Nair R, Bucheimer N, Tulsian P, Brown N, Chapp C, Hsu TC, Colburn NH. Young MR, et al. Mol Cell Biol. 2002 Jan;22(2):587-98. doi: 10.1128/MCB.22.2.587-598.2002. Mol Cell Biol. 2002. PMID: 11756554 Free PMC article.

3

Fra-1 a target for cancer prevention or intervention.

Young MR, Colburn NH. Young MR, et al. Gene. 2006 Sep 1;379:1-11. doi: 10.1016/j.gene.2006.05.001. Epub 2006 May 6. Gene. 2006. PMID: 16784822 Review.

4

Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis.

Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR Jr, Young MR, Colburn NH. Matthews CP, et al. Among authors: young mr. Cancer Res. 2007 Mar 15;67(6):2430-8. doi: 10.1158/0008-5472.CAN-06-0522. Cancer Res. 2007. PMID: 17363560

5

AP-1 a target for cancer prevention.

Matthews CP, Colburn NH, Young MR. Matthews CP, et al. Among authors: young mr. Curr Cancer Drug Targets. 2007 Jun;7(4):317-24. doi: 10.2174/156800907780809723. Curr Cancer Drug Targets. 2007. PMID: 17979626 Review.

6

A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits".

Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, Young MR, Colburn NH. Kang MI, et al. Among authors: young mr. Mol Cancer Ther. 2009 Mar;8(3):571-81. doi: 10.1158/1535-7163.MCT-08-0811. Epub 2009 Mar 3. Mol Cancer Ther. 2009. PMID: 19258426 Free PMC article.

7

Specific methylation events contribute to the transcriptional repression of the mouse tissue inhibitor of metalloproteinases-3 gene in neoplastic cells.

Pennie WD, Hegamyer GA, Young MR, Colburn NH. Pennie WD, et al. Among authors: young mr. Cell Growth Differ. 1999 Apr;10(4):279-86. Cell Growth Differ. 1999. PMID: 10319998

8

Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis.

Hsu TC, Young MR, Cmarik J, Colburn NH. Hsu TC, et al. Among authors: young mr. Free Radic Biol Med. 2000 May 1;28(9):1338-48. doi: 10.1016/s0891-5849(00)00220-3. Free Radic Biol Med. 2000. PMID: 10924853 Review.

9

Induced expression of dominant-negative c-jun downregulates NFkappaB and AP-1 target genes and suppresses tumor phenotype in human keratinocytes.

Li JJ, Cao Y, Young MR, Colburn NH. Li JJ, et al. Among authors: young mr. Mol Carcinog. 2000 Nov;29(3):159-69. doi: 10.1002/1098-2744(200011)29:3<159::aid-mc5>3.0.co;2-w. Mol Carcinog. 2000. PMID: 11108661

10

Suppression of p65 phosphorylation coincides with inhibition of IkappaBalpha polyubiquitination and degradation.

Hu J, Haseebuddin M, Young M, Colburn NH. Hu J, et al. Mol Carcinog. 2005 Dec;44(4):274-84. doi: 10.1002/mc.20142. Mol Carcinog. 2005. PMID: 16163708

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

428 results

Search Page

Filters